J Korean Ophthalmol Soc > Volume 56(8); 2015 > Article
Journal of the Korean Ophthalmological Society 2015;56(8):1208-1214.
DOI: https://doi.org/10.3341/jkos.2015.56.8.1208    Published online August 15, 2015.
Efficacy of Intravitreal Dexamethasone Implant for Macular Edema Due to Branch Retinal Vein Occlusion According to Symptom Duration.
Soo Hyun Kwon, Jae Pil Shin, In Taek Kim, Dong Ho Park
Department of Ophthalmology, Kyungpook National University School of Medicine, Daegu, Korea. sarasate2222@gmail.com
망막분지정맥폐쇄에 의한 황반부종에서 덱사메타손 주입술 후 유병기간에 따른 임상경과 비교
권수현⋅신재필⋅김인택⋅박동호
경북대학교 의학전문대학원 안과학교실
Received: 6 February 2015   • Revised: 20 March 2015   • Accepted: 19 June 2015
Abstract
PURPOSE
To evaluate the efficacy of intravitreal dexamethasone implants for the treatment of macular edema (ME) due to branch retinal vein occlusion (BRVO) according to the duration of symptoms. METHODS: Thirty-one patients who received an intravitreal dexamethasone implant for ME due to BRVO were included in this retrospective study. The patients were divided into 2 groups. Group A included eyes with symptom duration less than 12 weeks and Group B included eyes with symptom duration of 12 weeks or longer. The main efficacy outcomes such as best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline and every 4 weeks over 24 weeks. Retreatment criteria included an increased CMT of 150 microm or reduction of logarithm of the minimal angle of resolution (log MAR) scores of at least 0.2. RESULTS: The CMT and BCVA improved significantly at each follow-up compared with the baseline (p < 0.001, p < 0.05, respectively). At 4 and 8 weeks after the first injection, CMT in Group A (285.3 +/- 19.9, 276.1 +/- 23.1 microm, respectively) was less than in Group B (310.3 +/- 37.5, 318.1 +/- 39.6 microm; p = 0.033, p = 0.001, respectively). At 4 weeks, the BCVA in Group A was better than in Group B (p = 0.009). Rate and timing of recurrence were not different between the 2 groups (p > 0.05). At 24 weeks, Group A showed less CMT and better BCVA compared with Group B (p = 0.043, p = 0.041, respectively). CONCLUSIONS: The intravitreal dexamethasone implant significantly reduced the CMT and improved BCVA in patients with ME due to BRVO. Patients with shorter symptom duration showed better anatomical and functional outcomes over 24 weeks. Early treatment with the intravitreal dexamethasone implant could produce better clinical results.
Key Words: Branch retinal vein occlusion;Dexamethasone;Macular edema;Recurrence


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next